KTN and the Biopharmaceutical Formulation Group hosted a webinar on 7th July on ‘Formulation challenges for delivery of RNA therapies’.

The therapeutic potential of different forms of RNA has been studied since the 1990s resulting in the first regulatory approval at the end of that decade. Since then, several RNA-based therapeutics have been approved, mainly treating rare genetic or infectious diseases. One of the challenges for RNA therapeutics is their efficient and targeted delivery, and formulation is therefore crucial to their success.

 

This half-day webinar on 7th July covered the different approaches used for RNA formulation, their application to molecules in clinical development, including for the treatment of Covid-19, as well as to marketed products. In addition to the presentations, there were Technology Highlights from UK SMEs presenting novel approaches that may contribute to future RNA formulations. Speakers included KTN’s Marcel Kuiper and Dr. Anna Blakney of Imperial College London.

 

You can view the recording here.

 

Event Agenda

13:30 – 13:35 Opening РMarcel Kuiper (KTN)

13:35 – 14:05 Formulation, scale-up and manufacturing considerations of RNA delivery systems РYvonne Perrie (University of Strathclyde)

14:05 – 14:25 Technology Highlights:

Deep eutectic solvents as novel RNA formulation reagents - Andrew Goldsborough (RNAssist)

Formulation of peptide/RNA nanoparticles - Helen McCarthy (pHion Therapeutics)

Cell and tissue delivery of RNA using Nanocin - Liam Good (Tecrea)

Nuvec®: a unique silica nanoparticle delivery system for nucleic acids РNigel Theobald (N4 Pharma)

14:25 – 14:35 Break

14:35 – 14:55 A self-amplifying RNA LNP vaccine for the prevention of SARS-CoV-2 infection РAnna Blakney (Imperial College London)

14:55 – 15:25 Bringing mRNA therapeutics into the clinic: turning formulation challenges into opportunities РGeorge Dakwar (eTheRNA immunotherapies)

15:25 – 15:30 Close РChris van der Walle (GlaxoSmithKline)

15:30 – 17:00 1:1 participant video chats

 

This webinar was organised by the Biopharmaceutical Formulation Group and supported by the KTN’s Medicines Manufacturing Challenge Community.

 

You can view back the recording here.

Share this article